25 cents valuation - MST Report, page-2

a quick breakdown on this assessment.

1 expected revenue
2024 - $6.5m............2025 - $12.5m......... 2026 - $20m

2. expected ongoing expenses at approximately $13m per year

3. expected ROE
2025 - 33%............2026 - 58.7%

4. expected return on assets
2025 - 20%..........2026 - 46.2%

and the number of small molecule drugs, as ACR targets small molecule, coming off patent in the following years. thus potential for future development
2024 - 255..........2025 - 318..........2026 - 383. Wonder if Jublia is one of these? I have no idea if the figures mentioned above are viable.

but with the possibility of our Elma Generic having close to 50% of the US$39M market, our Dapson 5% having FDA approval and being launched 1st Qtr 2024, 3 more dossiers currently awaiting FDA approval, the millions being spent on our product pipeline...... an estimated share price value of 0.25cents per share seems............?

It is now only some 8 days away form our AGM. I would like to see ACR management put some figures($) on how the Elma Generic is going. The total shared costs so far and the total shared revenue with our partner Padagis, seeing how our Elma Generic was launched in the US, 11 MONTHS AGO. Jet.